Is Immatics N.V. (IMTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 45.7% / 30% | 0.5% / 30% | 16.04% / 5% | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 45.7% / 33% | 0.5% / 33% | 16.04% / 5% | ✗ NOT HALAL |
| MSCI | 2.3% / 33% | 86.8% / 33% | 1.0% / 33% | 16.04% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 45.7% / 33% | 0.5% / 33% | 16.04% / 5% | ✗ NOT HALAL |
| FTSE | 2.3% / 33% | 86.8% / 33% | 1.0% / 50% | 16.04% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -280.9% | |
| Operating Margin | -196.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -37.1% | |
| Return on Assets (ROA) | -18.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$177M |
| Free Cash Flow | -$183M |
| Total Debt | $16M |
| Debt-to-Equity | 3.2 |
| Current Ratio | 11.7 |
| Total Assets | $562M |
Price & Trading
| Last Close | $9.77 |
| 50-Day MA | $9.84 |
| 200-Day MA | $8.47 |
| Avg Volume | 451K |
| Beta | 1.4 |
|
52-Week Range
$3.30
| |
About Immatics N.V. (IMTX)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immatics N.V. (IMTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immatics N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immatics N.V.'s debt ratio?
Immatics N.V.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.3%.
What are Immatics N.V.'s key financial metrics?
Immatics N.V. has a market capitalization of $1.3B, and revenue of $48M. Return on equity stands at -37.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.